Genetic modulation of soluble Aβ rescues cognitive and synaptic impairment in a mouse model of AD by Stephanie Fowler et al.
ORAL PRESENTATION Open Access
Genetic modulation of soluble Ab rescues
cognitive and synaptic impairment in a mouse
model of AD
Stephanie Fowler1, Angie Chiang1, Ricky Savjani1,2, Megan Larson3,4, Dorothy Schuler5, John Cirrito5,
Sylvain Lesne3,4, Joanna Jankowsky1,6*
From Molecular Neurodegeneration: Basic biology and disease pathways
Cannes, France. 10-12 September 2013
Background
There has been a longstanding debate on whether amyloid
plaques are pathogenic by causing physical damage to
surrounding tissue or protective by sequestering more
toxic soluble forms of amyloid b (Ab) peptide. Numerous
studies in mouse models have documented a complex
relationship between soluble Ab, deposited aggregates, and
cognitive decline, but few experimental systems have been
capable of dissecting how each form of the peptide contri-
butes to the progressive memory deficits of Alzheimer’s
disease. Here we use a controllable transgenic model
expressing a mutant form of amyloid precursor protein
(APP) to distinguish the impact of APP and soluble Ab
from that of deposited amyloid on cognitive function and
synaptic structure.
Materials and methods
We created a transgenic model in which the tetracycline
transactivator drives expression of APPswe/ind in neurons
throughout the forebrain. After 6 months of transgene
expression when amyloid burden reached approximately
10%, we placed half of the mice on doxycycline to suppress
further production of transgenic APP and human Ab. All
animals were then tested for cognitive function using the
Morris water maze, radial arm water maze, and fear con-
ditioning. Once testing was complete, we harvested the
mice to examine amyloid pathology, synapse density,
oligomeric Ab, and synaptic protein levels.
Results
Doxycycline treatment suppressed expression of trans-
genic APP by > 90% and diminished production of human
Ab by 70% while leaving pre-existing amyloid deposits
intact. Remarkably, this treatment restored cognitive per-
formance to the level of healthy controls in all of the beha-
vioral tasks examined. Cognitive improvement coincided
with reduced levels of synaptotoxic Ab oligomers, greater
synaptic density surrounding amyloid plaques, and
increased expression of pre- and post-synaptic markers.
To demonstrate that recovery was due to reduction of Ab
and not simply suppression of APP, we treated a second
cohort of mice with the g-secretase inhibitor LY411575
and observed similar although somewhat less complete
recovery in both Morris water maze and synaptic markers.
Finally, transgene suppression normalized activation of the
actin-depolymerizing protein cofilin in a PAK-independent
manner, suggesting that APP/oAb may alter synaptic
structure through the opposing Rho/ROCK pathway.
Conclusions
These findings indicate that transient forms of APP and
Ab underlie much of the behavioral and synaptic recovery
observed in this model. Our work further suggests that
residual amyloid deposits need not be removed for suc-
cessful intervention at this early stage of disease.
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